Pediatrix Medical Group (NYSE:MD) Price Target Raised to $18.00

Pediatrix Medical Group (NYSE:MD) had its price objective raised by Jefferies Financial Group from $14.00 to $18.00 in a research report released on Tuesday,Benzinga reports. The firm currently has a buy rating on the stock.

Other research analysts have also issued reports about the company. StockNews.com upgraded Pediatrix Medical Group from a “sell” rating to a “hold” rating in a report on Wednesday, August 7th. UBS Group boosted their price objective on shares of Pediatrix Medical Group from $9.00 to $10.50 and gave the company a “neutral” rating in a research report on Friday, August 9th. Truist Financial increased their target price on Pediatrix Medical Group from $13.00 to $16.00 and gave the stock a “hold” rating in a report on Monday. Mizuho boosted their price target on Pediatrix Medical Group from $13.00 to $15.00 and gave the company a “neutral” rating in a report on Monday. Finally, Deutsche Bank Aktiengesellschaft increased their price objective on Pediatrix Medical Group from $9.00 to $15.00 and gave the stock a “hold” rating in a report on Monday. Five investment analysts have rated the stock with a hold rating and one has given a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $16.10.

Pediatrix Medical Group Trading Down 0.5 %

NYSE MD traded down $0.08 on Tuesday, reaching $15.96. The company had a trading volume of 23,679 shares, compared to its average volume of 869,343. The company has a quick ratio of 1.38, a current ratio of 1.42 and a debt-to-equity ratio of 0.83. Pediatrix Medical Group has a 52 week low of $6.62 and a 52 week high of $16.41. The stock has a market cap of $1.37 billion, a price-to-earnings ratio of -5.24, a PEG ratio of 2.35 and a beta of 1.55. The stock’s 50 day moving average is $11.99 and its 200-day moving average is $9.59.

Pediatrix Medical Group (NYSE:MD) last released its quarterly earnings data on Friday, November 1st. The company reported $0.44 earnings per share for the quarter, topping the consensus estimate of $0.37 by $0.07. Pediatrix Medical Group had a negative net margin of 12.65% and a positive return on equity of 12.79%. The business had revenue of $511.20 million for the quarter, compared to analyst estimates of $498.87 million. During the same quarter last year, the firm earned $0.29 EPS. Pediatrix Medical Group’s quarterly revenue was up .9% compared to the same quarter last year. Equities analysts predict that Pediatrix Medical Group will post 1.19 earnings per share for the current year.

Insider Buying and Selling

In other news, CEO James D. Swift sold 11,100 shares of the company’s stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $10.79, for a total transaction of $119,769.00. Following the sale, the chief executive officer now owns 170,001 shares in the company, valued at $1,834,310.79. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. In other news, CFO C Marc Richards sold 17,438 shares of the firm’s stock in a transaction that occurred on Monday, August 12th. The stock was sold at an average price of $10.08, for a total value of $175,775.04. Following the completion of the sale, the chief financial officer now directly owns 175,347 shares of the company’s stock, valued at $1,767,497.76. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO James D. Swift sold 11,100 shares of Pediatrix Medical Group stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $10.79, for a total value of $119,769.00. Following the transaction, the chief executive officer now owns 170,001 shares of the company’s stock, valued at $1,834,310.79. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 35,538 shares of company stock worth $373,664. Corporate insiders own 1.20% of the company’s stock.

Institutional Investors Weigh In On Pediatrix Medical Group

Hedge funds have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets raised its position in shares of Pediatrix Medical Group by 79.2% in the first quarter. BNP Paribas Financial Markets now owns 41,728 shares of the company’s stock valued at $419,000 after purchasing an additional 18,438 shares during the period. Empowered Funds LLC raised its holdings in Pediatrix Medical Group by 8.2% in the 1st quarter. Empowered Funds LLC now owns 235,124 shares of the company’s stock valued at $2,358,000 after acquiring an additional 17,784 shares during the period. Oppenheimer Asset Management Inc. lifted its position in Pediatrix Medical Group by 4.5% during the first quarter. Oppenheimer Asset Management Inc. now owns 72,767 shares of the company’s stock worth $730,000 after acquiring an additional 3,142 shares during the last quarter. Illinois Municipal Retirement Fund boosted its holdings in shares of Pediatrix Medical Group by 8.8% during the first quarter. Illinois Municipal Retirement Fund now owns 49,526 shares of the company’s stock worth $497,000 after acquiring an additional 4,013 shares during the period. Finally, ProShare Advisors LLC grew its position in shares of Pediatrix Medical Group by 7.4% in the first quarter. ProShare Advisors LLC now owns 16,937 shares of the company’s stock valued at $170,000 after purchasing an additional 1,167 shares during the last quarter. Institutional investors and hedge funds own 97.71% of the company’s stock.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.